18F-DOPA II - PET Imaging Optimization
Recruiting now Phase 3 NCT04706910
Run by University of Alberta · for All ages · All sexes
What this study is about
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism. 2. Pediatric patients (less than 18 years old) with neuroblastoma. 3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor. 4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia. 5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors. Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.
Who can join (things the study team will check)
✅ You may be able to join if…
- Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
- Pediatric patients (less than 18 years old) with neuroblastoma.
- Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.
- Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.
- Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.
🚫 You may not be able to join if…
- Unable to obtain consent
- Weight >225 kg (weight limitation of PET/CT scanner)
- Adult patients unable to lie flat for 20-30 minutes to complete the PET-CT session.
- Young pediatric patients (less than 13 years old) who are unable to lie flat for 20-30 minutes and for whom clinical sedation is contraindicated (as determined by a pediatric anaesthesiologist).
- Lack of intravenous access
- History of previous cholecystectomy (excluded from dynamic abdomen sub-study only)
- Pregnancy
Where this trial is running
- WC Mackenzie Health Science Centre / University of Alberta Hospital, Edmonton, Alberta, Canada
Who to contact
Jonathan Abele, MD · 1-780-407-6907 · jabele@ualberta.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04706910.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.